Company profile: Microbiotica
1.1 - Company Overview
Company description
- Provider of human microbiome therapeutics and biomarkers, offering live bacterial therapeutics that engraft in the intestine; microbiome-based biomarkers for drug response, side-effects, or disease progression to stratify patients; a gut bacteria Culture Collection and proprietary Reference Genome Database; advanced microbiome bioinformatics and machine learning; and Personalised Bacterial Banks.
Products and services
- Live Bacterial Therapeutics: Clinical-grade consortia of precision-selected gut bacteria built for oral administration that engraft in the intestine to treat diseases, targeting phenotype-linked strains
- Microbiome Bioinformatics and Machine Learning: Research-grade computational systems analyze clinical datasets using advanced bioinformatics and machine learning to identify bacterial signatures linked to patient phenotypes
- Microbiome-based Biomarkers: Custom-engineered biomarkers derived from clinical datasets stratify patients for personalized treatment by drug response, side-effects, and disease progression, enabling precision patient selection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Microbiotica
Idenix
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on discovering and developing drugs to treat human viral diseases, with an emphasis on hepatitis C virus (HCV), with operations in the United States and Europe.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idenix company profile →
Elucigene
HQ: United Kingdom
Website
- Description: Provider of clinical diagnostic assays and product realisation services, offering kits for cystic fibrosis (CFTR mutations), rapid aneuploidy analysis (QF-PCR for trisomies 21, 18, 13 and sex chromosome aneuploidies), reproductive health (recurrent miscarriage, male infertility, Y-microdeletion), and genetic disease diagnosis (thrombophilia, alpha-1-antitrypsin). Services include assay development, validation, manufacturing, regulatory strategy, and commercial sale and distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elucigene company profile →
Solid Biosciences
HQ: United States
Website
- Description: Provider of gene therapy candidates and research focused on rare genetic diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solid Biosciences company profile →
Presidio Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics for viral infections, including HCV and HIV, discovering, developing, and commercializing treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Presidio Pharmaceuticals company profile →
Guardant Health
HQ: United States
Website
- Description: Provider of precision oncology diagnostics, including Shield, an FDA-approved blood test for colorectal cancer screening; Guardant Reveal for MRD in early-stage cancers; Guardant360 CDx, an FDA-approved liquid biopsy for comprehensive genomic profiling in advanced solid tumors; Guardant360 Response for treatment monitoring; Guardant360 TissueNext with AI-powered PD-L1 detection; and Guardant Infinity for biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Guardant Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Microbiotica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Microbiotica
2.2 - Growth funds investing in similar companies to Microbiotica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Microbiotica
4.2 - Public trading comparable groups for Microbiotica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →